David A Waltz MD
Pediatric Asthma Pulmonology
Assistant Clinical Professor of Pediatrics, Boston Children's Hospital
Join to View Full Profile
300 Longwood AveBoston, MA 02115
Phone+1 617-355-1900
Fax+1 617-730-0084
Dr. Waltz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Pulmonology, 1988 - 1991
University of Rochester Medical CenterResidency, Pediatrics, 1985 - 1988
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
Certifications & Licensure
MA State Medical License 1988 - 2021
Clinical Trials
- A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis Start of enrollment: 2000 Feb 01
Publications & Presentations
PubMed
- 64 citationsEfficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-wee...Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor
The Lancet. Respiratory Medicine. 2022-03-01 - 135 citationsTriple Therapy for Cystic Fibrosis Phe508del -Gating and -Residual Function Genotypes.Peter J. Barry, Marcus A. Mall, Antonio Álvarez, Carla Colombo, Karin M. de Winter-de Groot
The New England Journal of Medicine. 2021-08-25 - 146 citationsA Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.Edith T. Zemanick, Jennifer L. Taylor-Cousar, Jane Davies, Ronald L. Gibson, Marcus A. Mall
American Journal of Respiratory and Critical Care Medicine. 2021-06-25
Grant Support
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study Of DenNational Center For Research Resources2006
- Duration Of Antimicrobial Treatment Effect Following Administration Of Tobi SoluNational Center For Research Resources2005
- A Phase 2 Randomized Double Blind Parallel Dose Ranging Study Of Oral Theraclec-National Center For Research Resources2005
- 24 Weeks Of Oral Treatment With Biil 284 Bs In Adult And Pediatric CFNational Center For Research Resources2005
- A Multi-Center, Dbl-Blind, Randomized, Placebo-Controlled, 28-Day Study Of Ins37National Center For Research Resources2004–2005
- Duration/Effect Antimicrobial Tx Following Tobramycin InNational Center For Research Resources2004
- A Randomized, Db-Blind, Placebo-Controlled Study To Investigate The Efficacy OfNational Center For Research Resources2004
- A Phase IA Study Of Multiple Ascending Doses Of Nacystelyn In CF PatientsNational Center For Research Resources2004
- Inhaled Ib-367 In Adults With Cystic FibrosisNational Center For Research Resources2000–2002
- Urokinase--A Link Between Cell Adhesion And ProteolysisNational Heart, Lung, And Blood Institute1994–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
